Additional use of molecular biomarkers (p53, cyclinA, aneuploidy) in mucosal biopsies targeted by the AFI-guided pCLE might improve the accuracy of the diagnosis for inconspicuous dysplastic BE with an AUC of 0.83 compared to those of the conventional protocol. This evidence concerns the gene TP53 and Barrett esophagus.